RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.77
+0.01 (+0.54%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.76
Open2.76
Bid2.70 x 3000
Ask2.88 x 500
Day's Range2.75 - 2.86
52 Week Range2.51 - 7.70
Volume157,233
Avg. Volume317,122
Market Cap11.788M
Beta0.91
PE Ratio (TTM)N/A
EPS (TTM)-8.05
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.00
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    RXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma

    - Scientists demonstrate the potential of improving therapy with patient-derived tumor infiltrating lymphocytes (TILs) by applying RXi's novel sd-rxRNA compounds specific to PD-1. Targeting the PD-1/PD-L1 ...

  • PR Newswire10 days ago

    RXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering

    MARLBOROUGH, Mass., April 11, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today the closing of its previously announced registered direct offering of shares of common stock priced at-the-market for gross proceeds of approximately $4.9 million. RXi issued 1,510,604 shares of common stock, par value $0.0001 per share, at a price of $3.15 per share. Additionally, in a concurrent private placement offering, RXi issued unregistered warrants to purchase a total of 1,132,953 shares of common stock, representing 75% of the shares of common stock purchased in the registered offering.

  • PR Newswire12 days ago

    RXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market

    MARLBOROUGH, Mass., April 9, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, announced today that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,510,604 shares of its common stock, at a purchase price per share of $3.24375, for gross proceeds of approximately $4.9 million, in a registered direct offering priced at-the-market. Additionally, RXi has also agreed to issue to the investors unregistered warrants to purchase up to 1,132,953 shares of common stock. The warrants have an exercise price of $3.15 per share of common stock, shall be exercisable immediately and will expire on the earlier of five and one-half years from the issuance date and 5 years from the date a registration statement registering the shares of common stock underlying the warrants becomes effective.

  • ACCESSWIRE16 days ago

    Today’s Research Reports on Trending Tickers: Vericel Corporation and RXi Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / April 5, 2018 / After falling sharply on global trade fears in early trading Wednesday, U.S. stocks rallied to close in the green. The Dow Jones Industrial Average touched a ...

  • Zacks Small Cap Research17 days ago

    RXII: TIL Program Moving Forward while Waiting on Partnerships

    RXi reported revenues of $15,000 for the year from grants related to BioAxone’s work in spinal cord injury, compared to $19,000 in revenues in 2016. Research and development expenses were $5.4 million for the full year, flat with the prior period’s amount. The addition of the immuno-oncology program from MirImmune was offset by lower spending on clinical trial related expenses as patient visits in each of the company’s ongoing clinical trials came to an end.

  • PR Newswire17 days ago

    RXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference

    Poster presentations will include data from the Company's Phase 2 study with RXI-109 for the reduction of hypertrophic scars, its Phase 2 study with Samcyprone™ for the treatment of cutaneous warts and ...

  • Thomson Reuters StreetEvents24 days ago

    Edited Transcript of RXII earnings conference call or presentation 26-Mar-18 9:00pm GMT

    Q4 2017 Rxi Pharmaceuticals Corp Earnings Call

  • PR Newswire25 days ago

    RXi Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Recent Corporate Highlights

    MARLBOROUGH, Mass. , March 26, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering ...

  • ACCESSWIRE26 days ago

    RXi Pharmaceuticals Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 26, 2018 / RXi Pharmaceuticals Corporation (NASDAQ: RXII ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 26, 2018, at 5:00 PM ...

  • ACCESSWIRElast month

    RXi Pharmaceuticals Discusses the Immuno-Oncology Space and Target Indications in New SNNLive Video Interview with StockNewsNow.com

    LOS ANGELES, CA / ACCESSWIRE / March 22, 2018 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Geert Cauwenbergh, Dr. Med. Sc., President and CEO ...

  • PR Newswirelast month

    RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2017 Financial Results on Monday, March 26, 2018

    MARLBOROUGH, Mass., March 21, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will report its financial results for the fourth quarter and year ended December 31, 2017, and provide a business update on March 26, 2018 after the close of the U.S. financial markets. The webcast link is available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com.  The event may also be accessed by dialing toll-free in the United States: +1 (844) 376-4678.

  • PR Newswirelast month

    RXi Pharmaceuticals Selected to Present at the Landmark Venture Forum

    MARLBOROUGH, Mass., March 20, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform announced today that Dr. Geert Cauwenbergh, RXi's President and CEO, will present at the Landmark Venture Forum hosted by Landmark Angels. The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com, approximately 1 hour following the presentation.

  • TheStreet.comlast month

    Focused on Speculative Trading: RXII, BB, CASA

    We have this drifting action and uncorrelated action between stocks and the indices.

  • ACCESSWIRElast month

    Today’s Research Reports on Trending Tickers: Novavax and RXi Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / March 15, 2018 / U.S. markets' slide extended on Wednesday as concerns over a potential trade war with China continues to grow. The Dow Jones Industrial Average dropped 1.00 ...

  • RXi Pharmaceuticals Corporation (NASDAQ:RXII): Does The -60.33% Earnings Decline Make It An Underperformer?
    Simply Wall St.last month

    RXi Pharmaceuticals Corporation (NASDAQ:RXII): Does The -60.33% Earnings Decline Make It An Underperformer?

    Today I will examine RXi Pharmaceuticals Corporation’s (NASDAQ:RXII) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, in addition toRead More...

  • Zacks Small Cap Research2 months ago

    RXII: Exploiting a Natural Mechanism: RXi’s sd-rxRNA

    RXi’s most advanced efforts are represented by two Phase II assets in dermal scarring and warts and a Phase I/II asset in an ocular indication.  The first two indications are associated with RXI-109 and the last with Samcyprone.  In December 2017, RXi provided favorable topline data for its Phase IIa trial for hypertrophic scars.  We anticipate that RXI-109 will advance to a Phase IIb then a Phase III trial in the two lead indications in 2018 and 2019 and achieve eventual approval and commercialization in 2023.

  • PR Newswire2 months ago

    RXi Pharmaceuticals to Present at the BIO CEO and Investor Conference

    MARLBOROUGH, Mass., Feb. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will give a webcast presentation at the BIO CEO and Investor Conference.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Regains Compliance with NASDAQ Listing Requirements

    MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing RNAi-based immunotherapies to treat cancer, today announced that it received a notice from the NASDAQ Stock Market that the closing bid price of the Company's common stock has been at $1.00 per share or greater for ten consecutive days.  Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.

  • PR Newswire3 months ago

    RXi Pharmaceuticals to Present at Immuno-Oncology Frontiers World Conference

    MARLBOROUGH, Mass., Jan. 17, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced that it will give an oral presentation highlighting the company's proprietary therapeutic platform at the Immuno-Oncology Frontiers World conference.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth

    "After a thorough review of our business operations, development programs and financial resources, a decision was made to focus our efforts on RXi's expanding and promising immuno-oncology programs to accelerate growth and in turn support a return on investment for our shareholders," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals.  He stated that: "The positive clinical results recently announced from our Phase 2 dermatology study validate the safety and efficacy of our sd-rxRNA therapeutics in humans.

  • ACCESSWIRE3 months ago

    Blog Exposure - RXi Pharma to Execute Reverse Stock Split

    LONDON, UK / ACCESSWIRE / January 09, 2018 / Active-Investors.com has just released a free research report on RXi Pharmaceuticals Corp. (NASDAQ: RXII ). If you want access to this report all you need to ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Reverse Stock Split

    MARLBOROUGH, Mass., Jan. 5, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a clinical-stage company developing a new class of RNAi-based therapeutics, today announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split will become effective at 12:01 a.m. Eastern Time on January 8, 2018, and shares of RXi Pharmaceuticals common stock will trade on a post-split basis on the Nasdaq Capital Market under the Company's existing trading symbol, "RXII," at the market open on January 8, 2018. The new CUSIP number for the Company's common stock following the reverse stock split will be 74979C808.  In addition, pursuant to their terms, a proportionate adjustment will be made to the per share exercise prices and number of shares issuable under all of the Company's outstanding stock options and warrants to purchase shares of common stock.

  • PR Newswire4 months ago

    RXi Pharmaceuticals to Present at the 10th Annual Biotech Showcase Conference

    MARLBOROUGH, Mass., Dec. 29, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced that the Company's President and CEO, Dr. Geert Cauwenbergh, will present at the 10th Annual Biotech Showcase™. Taking place during one of the industry's largest annual healthcare investor conferences, this investor and partnering conference attracts pharmaceutical executives from around the world focused on investment and business development opportunities in the life sciences industry.  The conference will be held January 8–10, 2018 at the Hilton San Francisco Union Square, California. Dr. Cauwenbergh will present an overview of the Company's novel self-delivering RNAi (sd-rxRNA®) technology and the multiple business development and commercial opportunities available based on this proprietary platform.

  • PR Newswire4 months ago

    RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with RXI-109 for Dermal Scarring

    - RXI-109 is a self-delivering RNAi (sd-rxRNA) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation, and plays a key role in tissue regeneration and repair. - Study successfully meets primary effectiveness objective with statistically significant outcomes for improved visual appearance for RXI-109 treated scar over control. MARLBOROUGH, Mass., Dec. 18, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a clinical-stage company developing a new class of RNAi-based therapeutics today announced positive results with its lead clinical compound RXI-109 in a Phase 2 clinical trial.